相关实验视频

Updated: Jan 16, 2026

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

一种"功能优先"的方法来识别用于免疫治疗的调控性T细胞向抗体

Kirstie L S Cleary¹, Monika Semmrich², Linda Martensson²

¹Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.

Cancer immunology research

|September 26, 2025

概括

研究人员开发了一种新方法来制造抗体,这些抗体专门准并耗尽与瘤相关的调节性T (Treg) 细胞. 这种方法通过选择性地去除抑制细胞来增强癌症免疫疗法,从而改善瘤控制.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

癌症免疫疗法的有效性因瘤微环境而异,特别是抑制性调节性T (Treg) 细胞.
专门针对Tregs,同时节省效应T细胞是改善治疗结果的有希望的策略.

研究的目的:

产生和评估抗体,专门消耗与瘤相关的Tregs.
验证一个针对治疗性抗体开发的目标不可知抗体发现平台.

主要方法:

来自瘤携带小鼠的淋巴细胞与菌体抗体库一起用于产生抗体.
这就是F.I.R.S.T.T. 该平台评估了在临床前模型中的抗体选择性,特异性,Treg减弱疗效和瘤控制.
目标解卷确定了抗体的结合表位.

主要成果:

鉴定了24种具有不同特异性的抗体,从泛T细胞到瘤特异性Treg.
瘤Treg选择性,而不是相对结合,预测了Treg删除有效性和瘤控制.
一个抗体显示出强大的瘤特异性Treg耗尽,由Fc:FcγR相互作用介导,导致抗瘤效应.

结论:

目标不可知发现方法对于识别新型治疗抗体是有效的.
瘤特异性Treg消耗是增强癌症免疫疗法的可行策略.
针对ICAM-1表位体的已识别的抗体显示出对癌症治疗的潜力.

更多相关视频

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.